Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers

(2020) Nour K. Majbour et al.   Translational Neurodegeneration

Antibodies against alpha‐synuclein: tools and therapies

(2019) Nishant N. Vaikath et al.   JOURNAL OF NEUROCHEMISTRY

α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies

(2018) Inger van Steenoven et al.   MOVEMENT DISORDERS

CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes

(2017) Vasilios C. Constantinides et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations

(2017) Brit Mollenhauer et al.   MOVEMENT DISORDERS

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

(2017) Günter U. Höglinger et al.   MOVEMENT DISORDERS

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease

(2017) Nour K. Majbour et al.   Scientific Reports

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

(2016) Nour K. Majbour et al.   Molecular Neurodegeneration

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

(2016) Nour K. Majbour et al.   MOVEMENT DISORDERS

Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies

(2015) Urmi Sengupta et al.   BIOLOGICAL PSYCHIATRY

MDS clinical diagnostic criteria for Parkinson's disease

(2015) Ronald B. Postuma et al.   MOVEMENT DISORDERS

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

(2015) Tessandra Stewart et al.   Acta Neuropathologica Communications

Diagnostic Criteria for Vascular Cognitive Disorders

(2014) Perminder Sachdev et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

(2014) José Luis Molinuevo et al.   Alzheimers & Dementia

Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease

(2014) Yaroslau Compta et al.   JOURNAL OF NEUROLOGY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

(2014) Oskar Hansson et al.   Alzheimers Research & Therapy

Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease

(2014) Marta Swirski et al.   Alzheimers Research & Therapy

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

(2014) Jan O. Aasly et al.   Frontiers in Aging Neuroscience

Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy

(2013) Gesine Respondek et al.   MOVEMENT DISORDERS

Criteria for the diagnosis of corticobasal degeneration

(2013) M. J. Armstrong et al.   NEUROLOGY

The Diagnostic Value of CSF α-Synuclein in the Differential Diagnosis of Dementia with Lewy Bodies vs. Normal Subjects and Patients with Alzheimer’s Disease

(2013) Elisabeth Kapaki et al.   PLoS One

Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

(2012) Marta del Campo et al.   Biomarkers in Medicine

Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease

(2012) Min Jeong Park et al.   Journal of Clinical Neurology

Phosphorylated  -Synuclein in Parkinson's Disease

(2012) Y. Wang et al.   Science Translational Medicine

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease

(2011) Penelope G. Foulds et al.   FASEB JOURNAL

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

(2011) Brit Mollenhauer et al.   LANCET NEUROLOGY

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

(2011) Lucilla Parnetti et al.   MOVEMENT DISORDERS

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

(2010) Min Shi et al.   ANNALS OF NEUROLOGY

Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management

(2010) Olivier Piguet et al.   LANCET NEUROLOGY

Detection of elevated levels of  -synuclein oligomers in CSF from patients with Parkinson disease

(2010) T. Tokuda et al.   NEUROLOGY

Detection of elevated levels of soluble  -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies

(2009) K. E. Paleologou et al.   BRAIN

Central Role of α-Synuclein Oligomers in Neurodegeneration in Parkinson Disease

(2008) Aleksey G. Kazantsev et al.   ARCHIVES OF NEUROLOGY

Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood

(2008) Robin Barbour et al.   Neurodegenerative Diseases

Second consensus statement on the diagnosis of multiple system atrophy

(2008) S. Gilman et al.   NEUROLOGY